Esophageal carcinoma (squamous + adeno) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-LIFESTYLE-HOT-MATE-ESOPHAGEAL-PREVENTION-INTENSIFIED-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-19 | pending_clinical_signoff |
| Diseases | DIS-ESOPHAGEAL |
| Sources | SRC-NCCN-BCELL-2025 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
STUB — v0.3 IARC 2A probable-carcinogen batch (hot maté). IARC Group 2A probable — limited human evidence; clinical recommendation more conservative than Group 1. IARC Monograph 116 (2016) is the canonical evidence anchor; cited in notes only (not yet a separate SRC entity in KB). Two-Clinical-Co-Lead signoff queued per CHARTER §6.1 dev-mode exemption. No drug regimen — intervention is temperature-counseling + symptom-triggered evaluation.
Used By
No reverse references found in the YAML corpus.